Compare StocksABBV vs ABT

AbbVie Inc. (ABBV) vs Abbott Laboratories (ABT): Which Is the Better Buy in 2026?

As of 2026-08-03, ABBV is overvalued at $251, with a DCF intrinsic value of $178 and a margin of safety of -41%. ABT is overvalued at $106, with an intrinsic value of $89 and a margin of safety of -18%. Of the two, ABT has the wider margin of safety.

ABBV
AbbVie Inc.
$250.94
VS
ABT
Abbott Laboratories
$105.70

Rewards

ABBV
  • AbbVie Inc. has maintained ROIC above 10% for 4 consecutive years, suggesting solid business economics.
  • Gross margin of 72.8% indicates strong pricing power — typical of businesses with significant intellectual property or brand strength.
  • AbbVie Inc. scores 82/100 on the Economic Moat Score (Wide Moat), with reinvestment efficiency as the strongest competitive dimension.
ABT
  • Abbott Laboratories scores 86/100 on the Economic Moat Score (Wide Moat), with margin stability as the strongest competitive dimension.
  • Altman Z-Score of 5.60 indicates very low bankruptcy risk — the company is firmly in the safe zone.

Risks

ABBV
  • Buybacks have been poorly timed — 3 out of 4 years involved repurchases at relatively expensive valuations.
  • Free cash flow has declined at a 9.8% CAGR over the past 4 years — a concerning trend.
ABT
  • Trailing P/E of 34.2x is 26% above the historical average of 27.2x — the stock trades at a premium to its own history.
  • PEG ratio of 2.13 indicates the stock is expensive relative to its expected growth — the market may be pricing in more growth than analysts project.

Key Valuation Metrics

Learn more →
ABBV
ABT
Valuation
N/A
Free Cash Flow
$7.21B
N/A
FCF Yield
3.94%
70.89
Trailing P/E
34.21
15.41
Forward P/E
17.43
Quality & Moat
27.60%
ROIC
6.41%
N/A
ROE
10.58%
72.79%
Gross Margin
56.85%
0.41
PEG Ratio
2.13
Balance Sheet Safety
N/A
Net Debt / Equity
0.52
N/A
Interest Coverage
N/A
2.06
Net Debt / EBITDA
2.32
2.76%
Dividend Yield
2.38%
ABBV: 6Ties: 1ABT: 1
ABBVABT

Historical Fundamentals

Learn more →
ABBV

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

ABT

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

$1 Retained Earnings Test

Learn more →
ABBV
N/A
Net losses over 3 years — test not applicable
Company had negative cumulative retained earnings
Σ Retained
$-19.85B
Δ Market Cap
+$118.02B
Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
ABT
$1.89
created per $1 retained over 3 years
Value Creator
Σ Retained
$14.14B
Δ Market Cap
+$26.79B
Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

Discounted Cash Flow (DCF) Analysis

Learn more →
ABBV
40.7% Overvalued
Price is 40.7% above estimated fair value
Current Price: $250.94
Fair Value: $178.31
Strongly undervalued
Undervalued
Fairly valued
Overvalued
Strongly overvalued
ABT
18.2% Overvalued
Price is 18.2% above estimated fair value
Current Price: $105.70
Fair Value: $89.41
Strongly undervalued
Undervalued
Fairly valued
Overvalued
Strongly overvalued

Reverse DCF — Market-Implied Growth

Learn more →
ABBV

Requires positive FCF to compute implied growth rate.

ABT

What growth rate is the market pricing in at $106?

+12.3%
Market-Implied Owner Earnings Growth
Standard FCF implies +12.8%

The market implies +12.3% Owner Earnings growth, above historical trends.

Standard FCF implies a demanding +12.8%, reflecting heavy growth investment.

Economic Moat Score

Learn more →
ABBV
82/100
Wide Moat
70+ Wide · 40-69 Narrow · <40 None

Wide moat with strength across all dimensions. Reinvestment Efficiency is the standout factor.

Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.
ABT
86/100
Wide Moat
70+ Wide · 40-69 Narrow · <40 None

Wide moat with strength across all dimensions. Margin Stability is the standout factor.

Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.

Forensic Accounting

Learn more →
ABBV
-2.86
Unlikely Manipulator
Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

M-Score Trend

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.
ABT
-2.48
Unlikely Manipulator
Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

M-Score Trend

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

Ownership Breakdown

Learn more →
ABBV
Insiders 0.1%Institutions 76.9%Retail & Other 23.0%
No. of Institutional Holders5,146
High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.
ABT
Insiders 0.5%Institutions 83.0%Retail & Other 16.5%
No. of Institutional Holders3,843
High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.

High insider ownership aligns management incentives with shareholders. Institutional concentration can indicate smart-money conviction but also crowding risk.

Insider Buying Activity

Learn more →
ABBV
0
Buys (3M)
0
Buys (12M)
No open market insider purchases found.
Open market purchases · includes direct & indirect ownership · excludes option exercises
ABT
1
Buys (3M)
5
Buys (12M)
Total value (12M): $4.40M
STRATTON JOHN G.
Director
$173,640
@ $86.82 · 2026-05-07
STARKS DANIEL J
Director
$926,537
@ $92.65 · 2026-04-27
BOUDREAU PHILIP P
Chief Financial Officer
$201,300
@ $91.50 · 2026-04-23
STARKS DANIEL J
Director
$1.09M
@ $108.73 · 2026-02-04
FORD ROBERT B.
Chief Executive Officer
$2.01M
@ $107.13 · 2026-01-23
Open market purchases · includes direct & indirect ownership · excludes option exercises

Open market purchases · includes direct & indirect ownership · excludes option exercises.

Insider Selling Activity

Learn more →
ABBV
0
Sells (3M)
5
Sells (12M)
Total value (12M): $21.79M
PURDUE DAVID RYAN
Officer
$1.22M
@ $233.56 · 2026-03-04
SIATIS PERRY C.
General Counsel
$4.38M
@ $234.39 · 2026-03-02
SIATIS PERRY C.
General Counsel
$5.15M
@ $230.00 · 2026-02-25
SALEKI-GERHARDT AZITA
Chief Operating Officer
$8.41M
@ $198.42 · 2025-08-12
DONOGHOE NICHOLAS
Officer
$2.64M
@ $198.51 · 2025-08-05
STEWART JEFFREY RYAN
Officer
$12.36M
@ $210.08 · 2025-03-31
REENTS SCOTT T.
Chief Financial Officer
$3.75M
@ $212.34 · 2025-03-14
SIATIS PERRY C.
General Counsel
$5.82M
@ $208.69 · 2025-03-03
GONZALEZ RICHARD A
Director
$20.26M
@ $205.45 · 2025-03-03
RICHMOND TIMOTHY J
Officer
$4.47M
@ $210.45 · 2025-03-03
BUCKBEE KEVIN K
Officer
$3.85M
@ $203.41 · 2025-02-26
RICHMOND TIMOTHY J
Officer
$6.07M
@ $202.90 · 2025-02-26
SIATIS PERRY C.
General Counsel
$1.14M
@ $197.90 · 2025-02-20
BUCKBEE KEVIN K
Officer
$310,032
@ $172.24 · 2024-12-16
GONZALEZ RICHARD A
Officer and Director
$12.40M
@ $186.52 · 2024-08-05
Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives
ABT
0
Sells (3M)
8
Sells (12M)
Total value (12M): $1.44M
SALVADORI DANIEL GESUA SIVE
Officer
$102,288
@ $115.58 · 2026-03-02
MCCOY JOHN A. JR
Officer
$67,614
@ $115.58 · 2026-03-02
MORRONE LOUIS H
Officer
$132,224
@ $115.58 · 2026-03-02
SHROFF ERIC
Officer
$81,946
@ $115.58 · 2026-03-02
CUSHMAN ELIZABETH C
General Counsel
$30,398
@ $115.58 · 2026-03-02
MORELAND MARY K
Officer
$70,851
@ $115.58 · 2026-03-02
SHROFF ERIC
Officer
$203,043
@ $128.02 · 2025-11-25
BOUDREAU PHILIP P
Chief Financial Officer
$746,758
@ $134.55 · 2025-08-08
BLOUNT SALLY E
Director
$337,116
@ $129.66 · 2025-04-30
EARNHARDT LISA D
President
$12.23M
@ $133.83 · 2025-03-07
MCCOY JOHN A. JR
Officer
$77,652
@ $138.17 · 2025-03-03
SHROFF ERIC
Officer
$77,652
@ $138.17 · 2025-03-03
MORELAND MARY K
Officer
$109,292
@ $138.17 · 2025-03-03
MORRONE LOUIS H
Officer
$153,507
@ $138.17 · 2025-03-03
WAINER ANDREA F
Officer
$131,123
@ $138.17 · 2025-03-03
FORD ROBERT B.
Chief Executive Officer
$37.44M
@ $131.17 · 2025-02-05
SALVADORI DANIEL GESUA SIVE
Officer
$3.05M
@ $128.50 · 2025-01-30
ALLEN HUBERT L.
Officer
$24.34M
@ $128.26 · 2025-01-30
ALLEN HUBERT L.
Officer
$18.42M
@ $117.04 · 2024-10-21
FORD ROBERT B.
Chief Executive Officer
$16.49M
@ $116.41 · 2024-09-12
MCCOY JOHN A. JR
Officer
$3,100
@ $114.81 · 2024-09-04
Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives

Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives.

🎭 Mr. Market's Mood

Learn more →
ABBV
FearGreed
😏Greed(61/100)

"Market is optimistic — be cautious and ensure you have a margin of safety"

Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
ABT
FearGreed
😐Neutral(53/100)

"Market is pricing this stock without strong emotion in either direction"

Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

Composite sentiment score based on market signals. Inspired by Buffett’s "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

⚖️ Buffett Signal

Learn more →
ABBV
Awaiting DCF Data

The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

DCF Margin of Safety: N/AMr. Market's Mood: Greed (61)
ABT
Awaiting DCF Data

The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

DCF Margin of Safety: N/AMr. Market's Mood: Neutral (53)
View ABBV Full AnalysisView ABT Full Analysis

Frequently Asked Questions: ABBV vs ABT

Is AbbVie Inc. or Abbott Laboratories more undervalued in 2026?

Based on our discounted cash flow model, ABT trades at a -18.2% margin of safety (intrinsic value $89 vs. price $106), compared to ABBV's -40.7% margin of safety (intrinsic $178 vs. $251).

Which stock has a wider economic moat, AbbVie Inc. or Abbott Laboratories?

ABT scores 86/100 (Wide moat), while ABBV scores 82/100 (Wide moat). The moat score measures competitive advantage durability across ROIC consistency, margin stability, revenue predictability, and reinvestment efficiency.

Is AbbVie Inc. in financial distress?

ABBV's Altman Z-Score of 2.4 places it in the Grey zone, signaling elevated bankruptcy risk. ABT scores 5.6 (Safe zone). The Altman Z-Score is a five-factor model that predicts insolvency within two years; scores below 1.81 indicate significant distress.

Which stock has higher return on invested capital, AbbVie Inc. or Abbott Laboratories?

ABBV earns 27.6% ROIC versus ABT's 6.4%. A higher ROIC means the company generates more profit per dollar of capital employed, a hallmark of durable competitive advantage in Buffett-style analysis.

Which dividend is safer, AbbVie Inc.'s or Abbott Laboratories's?

ABT's dividend earns a safety score of 84/100 (Very Safe), compared to ABBV's 39/100 (Unsafe). ABT has raised its dividend for 3 consecutive years.

ABBV vs ABT: Which Is the Better Buy in 2026? | SafetyMargin.io